Vanguard Group’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-499,932
| Closed | -$136K | – | 4598 |
|
|
2022
Q3 | $136K | Buy |
499,932
+186,229
| +59% | +$73.7K | ﹤0.01% | 4466 |
|
|
2022
Q2 | $110K | Sell |
313,703
-7,900
| -2% | -$4K | ﹤0.01% | 4539 |
|
|
2022
Q1 | $218K | Sell |
321,603
-404,761
| -56% | -$444K | ﹤0.01% | 4525 |
|
|
2021
Q4 | $1.68M | Sell |
726,364
-4,208
| -0.6% | -$14.2K | ﹤0.01% | 4103 |
|
|
2021
Q3 | $3.35M | Buy |
730,572
+14,790
| +2% | +$65K | ﹤0.01% | 3872 |
|
|
2021
Q2 | $3.18M | Sell |
715,782
-83,943
| -10% | -$427K | ﹤0.01% | 3814 |
|
|
2021
Q1 | $5.82M | Buy |
799,725
+12,247
| +2% | +$101K | ﹤0.01% | 3452 |
|
|
2020
Q4 | $6.01M | Buy |
787,478
+453,636
| +136% | +$3.03M | ﹤0.01% | 3276 |
|
|
2020
Q3 | $3.03M | Sell |
333,842
-2,325
| -0.7% | -$17.6K | ﹤0.01% | 3364 |
|
|
2020
Q2 | $2.84M | Buy |
336,167
+19,220
| +6% | +$126K | ﹤0.01% | 3328 |
|
|
2020
Q1 | $1.57M | Buy |
316,947
+416
| +0.1% | +$3.23K | ﹤0.01% | 3362 |
|
|
2019
Q4 | $2.28M | Sell |
316,531
-1,805
| -0.6% | -$16.3K | ﹤0.01% | 3413 |
|
|
2019
Q3 | $3.44M | Buy |
318,336
+40,477
| +15% | +$433K | ﹤0.01% | 3272 |
|
|
2019
Q2 | $3.61M | Buy |
277,859
+7,588
| +3% | +$101K | ﹤0.01% | 3276 |
|
|
2019
Q1 | $2.67M | Buy |
270,271
+54,370
| +25% | +$506K | ﹤0.01% | 3358 |
|
|
2018
Q4 | $2.25M | Buy |
+215,901
| New | +$2.61M | ﹤0.01% | 3339 |
|
Vanguard Group's LOGC Position: Q4 2022 in Review
Vanguard Group sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 499,932 shares — an estimated $136K sold.
Vanguard Group first reported a position in LOGC in Q4 2018 and held it in 16 quarters. The position peaked at $6.01M in Q4 2020. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.
- Vanguard Group reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- Vanguard Group sold 499,932 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $136K.
- Vanguard Group first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 16 quarters.
- Vanguard Group's LogicBio Therapeutics, Inc. Common Stock position peaked at $6.01M in Q4 2020.
- 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.
Based on Vanguard Group's 13F filing for Q4 2022, filed 10 Feb 2023.